ALBRIOZA Commercial Launch

Germany Case Study High Unmet Need ~7,000 people living with ALS in Germany1, majority of patients diagnosed and initially treated in ~25 ALS centers of expertise • Focused Outreach to Key Physicians • • Engagement with top national KOLs, including KOLs at five participating PHOENIX trial sites Dividing country into six territories to target ~25 ALS centers of expertise and ~200 community-based neurologists that are responsible for the majority of Riluzole prescriptions Local team hired in Germany Commercial Launch Followed by Reimbursement Negotiations Preparing to commercialize in Germany after EU approval; free pricing at launch; reimbursement negotiations then typically take ~12 months following pricing and reimbursement dossier filing Husum Rostock Greifswaldy Itzehoe Neubrandenburg Bremerhaven Hamburg Schwerin Emden Bremen 2 Velzen Neuruppin Schwedt Meppen Vechta ♡ Hannover Rheine Bielefeld Stendal Berlin Frankfurt Luckenwalde Gosla Magdeburg Cottbus Bocholt Do trund Hoyerswerda Nordhausen Brilon Leipzig Kassel Vierse Dresden Erfurt Καλη Aachen Siegen ☆ +Chemnitz Bonn Fulda Frankfurt. Bayreuth Trier Würzburg Mannheim Nürnberg Saarbrücken Heilbronn Regensburg Stutgart Aalen Passau Pfaffenhofen Offenburg München- Traunreut Freiburg Lörrach Kempten 1. Rosenbohm et al, J Neurol (2017) 264:749-757, Epidemiology of amyotrophic lateral sclerosis in Southern Germany, 'ALS registry Swabia pts diagnosed 10/2008 - 12/2014', N=648 prospective patients were analyzed AMYLYX 17

View entire presentation